摘要
目的:探讨贝伐单抗联合顺铂对非小细胞肺癌胸腔积液的治疗作用。方法:选择82例非小细胞肺癌胸腔积液患者,随机分为观察组和对照组,各41例。对照组给予顺铂胸腔内注射,观察组给予贝伐单抗合顺铂胸腔内注入治疗。结果:观察组胸腔积液血管内皮生长因子平明显低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为26.83%,对照组为21.95%,差异有统计学意义(P<0.05)。结论:贝伐单抗联合顺铂对非小细胞肺癌胸腔积液控制效果较好,血管内皮生长因子可预测其治疗效果。
Objective： To investigate the therapeutic effect of bevacizumab combined with cisplatin onsmall cell lung cancer. Metliods： 82 patients with non small cell lung cancer were randomly divided into observation ses ）and control group（41 cases ）. The control group was given cisplatin intrapleural injection, the observation gvacizumab combined cisplatin intrapleural therapy. Results ： Observation group of pleural effusion vascular endothelial growth factor level was significantly lower than that of the control group （ P 〈 0. 05 ） . The incidence ratgroup was 26. 83%,and the control group was 21. 95% （ P 〈 0. 05 ） . Conclusion： Bevacizumab cosmall cell lung cancer pleural effusion has good control effect and vascular endothelial growth factor caeffect of treatment.
出处
《中国医药导刊》
2017年第4期377-378,共2页
Chinese Journal of Medicinal Guide
基金
秦皇岛科技局科研计划项目(课题编号2012023A195)
课题名称:终末期恶性肿瘤患者营养治疗
关键词
贝伐单抗铂
非小细胞肺癌胸腔积液
血管内皮生长因子
Bevacizumab platinum small cell lung cancer
Pleural effusion
Vascular endothelial growth factor
